HKB's NHP IBD Models offer pharmaceutical companies advanced translational platforms for developing therapeutics for Crohn's disease and ulcerative colitis. Our non-human primate models replicate key features of inflammatory bowel disease, including chronic intestinal inflammation, epithelial damage, and immune cell infiltration. These models support evaluation of biologics, small molecules, and novel immunomodulatory approaches.
HkeyBio is a China-based, globally-focused preclinical CRO dedicated exclusively to autoimmune and allergic diseases, with a unified service network across Asia, the Americas, Europe and Australia.
